BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1470 related articles for article (PubMed ID: 14734594)

  • 1. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
    van Dyck CH; Schmitt FA; Olin JT;
    Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
    Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
    CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
    Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
    Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
    Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
    Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
    Zhang N; Wei C; Du H; Shi FD; Cheng Y
    Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
    Jones R; Sheehan B; Phillips P; Juszczak E; Adams J; Baldwin A; Ballard C; Banerjee S; Barber B; Bentham P; Brown R; Burns A; Dening T; Findlay D; Gray R; Griffin M; Holmes C; Hughes A; Jacoby R; Johnson T; Jones R; Knapp M; Lindesay J; McKeith I; McShane R; Macharouthu A; O'Brien J; Onions C; Passmore P; Raftery J; Ritchie C; Howard R;
    Trials; 2009 Jul; 10():57. PubMed ID: 19630974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
    van Dyck CH; Tariot PN; Meyers B; Malca Resnick E;
    Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
    Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.